title: Case studies: orthopaedic surgery in adult patients with haemophilia A with inhibitors.
abstract: Whilst orthopaedic surgery in haemophilia patients without inhibitors is now relatively common in specialized centres, until recently there have been only a few sporadic instances of surgery having been undertaken on patients with inhibitors. The availability of recombinant activated factor VII (rFVIIa) for haemostatic cover during surgery allows procedures to be performed that previously may not have been considered possible. Complications associated with thrombosis are rare in haemophilia patients with inhibitors, but bleeding complications remain a concern. Globally, experience of performing orthopaedic surgery in these patients is increasing and many successful outcomes have been reported. However, more knowledge relating to the incidence and type of bleeding complications liable to be encountered, together with further information about appropriate rescue treatment, would be valuable. Data relating to long-term follow-up after surgery would be useful, as would a comparison of outcomes between haemophilia patients with and without inhibitors. Optimal dosing regimens for rFVIIa as surgical cover are still to be determined and further information is required relating to the cost effectiveness of rFVIIa in surgery. Further study should address these issues.
authors.affiliation: Department of Orthopaedics, Royal Free Hospital, London, UK. njgoddardfrcs@aol.com
authors.forename: N
authors.initials: N
authors.lastname: Goddard
mesh_terms: D000328:Adult; D000368:Aged; D019643:Arthroplasty, Replacement / Q000379:methods*; D019774:Blood Coagulation Factor Inhibitors / Q000097:blood*; D005167:Factor VII / Q000627:therapeutic use; D015942:Factor VIIa; D005260:Female; D006467:Hemophilia A / Q000097:blood / Q000150:complications* / Q000628:therapy; D006488:Hemostasis, Surgical / Q000379:methods; D006801:Humans; D008297:Male; D011994:Recombinant Proteins / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D019774:Blood Coagulation Factor Inhibitors; D011994:Recombinant Proteins; D005167:Factor VII; C103587:recombinant FVIIa; D015942:Factor VIIa